e抗原阳性及阴性慢性乙型肝炎患者临床特点比较

目的 分析HBeAg阴性及阳性CHB患者临床、病毒学及病理组织学特点。方法 对417例CHB患者的临床资料、肝功能和HBV DNA进行分析,并对47例HBeAg阴性和36例HBeAg阳性患者肝脏病理组织进行分析。结果 417例CHB患者中男性286例,女性131例。HBeAg阴性患者241例,占57．8％（241／417）,平均年龄（43．7±10.8）岁,病程（16．8±8．5）年。HBeAg阳性患者176例,占42．2%（176／417）,平均年龄（37．0±11．4）岁,病程（12．3±8．1）年。HBeAg阴性患者平均年龄及病程均高于HBeAg阳性患者,差异有统计学意义（t值分别为-6．20和-5．43, P值均〈0．01）。HBeAg阴性及阳性患者组ALT分别为（37．7±32．9）U／L和（82．1±107．6） U／L,差异有统计学意义（t=5．30,P〈0．01）,两组患者的ALT分布差异也有统计学意义（x^2= 40.21,P〈0．01）。HBV DNA大于103拷贝／ml的患者,HBeAg阴性组92例,占38．2％（92／241）, HBeAg阳性组166例,占94．3%（166／176）,HBeAg阴性组低于阳性组（x^2=180．33,P〈0．01）。47例HBeAg阴性患者肝组织炎症活动度G1-G4分别为5、27、14、1例,肝组织纤维化程度S1-S4分别为10、12、5、20例;36例HBeAg阳性组G1-G4分别为5、14、15、2例,S1-s4分别为8、12、6、10例,差异均无统计学意义（x^2值分别为3．09和2．23,P值均〉0．05）。结论 应重视对HBV DNA低复制的HBeAg阴性的CHB患者的随访和治疗。

An analysis of clinical features in HBeAg-negative and HBeAg-positive chronic hepatitis B

OBJECTIVES: To analyze the frequency and the clinical and virological features of HBeAg-negative and HBeAg-positive chronic hepatitis B. METHODS: Four hundred and seventeen chronic hepatitis B patients, 286 males and 131 females seen in our center were studied. Liver biopsies were taken from 83 patients. RESULTS: The cases with HBeAg-negative chronic hepatitis B were 241 (57.8%), with an average age of 43.7+/-10.8 and a history of 16.8+/-8.5 years. HBeAg-positive chronic hepatitis B cases were 176 (42.2%), with an average age of 36.95+/-11 and a history of 12.3+/-8.0 years. HBeAg-negative patients were significantly older (P < 0.01) in age and had a longer disease history. ALT levels and the percentage of HBV DNA were higher than 10(5) copies/ml in HBeAg-negative patients and were significantly lower than those in the HBeAg-positive patients (37.66+/-32.93) U/L vs. (82.09+/-107.57) U/L, 38.2% vs. 94.3%, P < 0.01]. Liver biopsies from 47 HBeAg-negative patients showed that the number of cases with inflammation scores of G1, G2, G3 and G4 were 5, 27, 14, 1 and the number of cases with fibrosis scores of S1, S2, S3 and S4 were 10, 12, 5, 20, respectively. In the 36 HBeAg-negative patients the respective number of cases with inflammation scores of G1, G2, G3 and G4 were 5, 14, 15, 2, and with fibrosis scores of S1, S2, S3, S4 were 8, 12, 6, 10. Although histopathological inflammation and fibrosis scores had no statistical difference between HBeAg-negative and positive patients (P > 0.05), 53.2% patients of HBeAg-negative group and 44.5% patients of HBeAg-positive group had a fibrosis score of >or= S3. CONCLUSION: Despite lower serum ALT and HBV DNA, HBeAg-negative chronic hepatitis B still has a significant disease progression. This observation may help to develop better clinical management in HBeAg-negative chronic hepatitis B patients.